Specialty Chemicals company Anupam Rasayan India announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total revenue for Q4FY25 was at Rs 5,057 million as compared to Rs 4,130 million in Q4FY24; up 22% YoY. EBITDA (incl. other income) was at Rs 1,500 million in Q4FY25 as compared to Rs 1,047 million in Q4FY24, up 43% and this would translate into 30% EBITDA margin in this quarter. Profit After Tax was at Rs 629 million in Q4FY25 as compared to Rs 405 million in Q4FY24; up 56% YoY. FY25 Financial Highlights: Total revenue for FY25 was at Rs 14,485 million as compared to Rs 15,053 million in FY24; down 4% YoY. EBITDA (incl. other income) was at Rs 4,123 million in FY25 as compared to Rs 4,109 million in FY24, this would translate into 28% EBITDA margin in FY25. Profit After Tax was at Rs 1,600 million in FY25 as compared to Rs 1,674 million in FY24. Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Consolidated revenue for the quarter Q4FY25 stood at Rs 506 crores registering a growth of 22% YoY and 31% QoQ. Consolidated revenue for the full year FY25 stood at Rs 1,448 crores registering a degrowth of 4% YoY. This performance was supported by growth in pharma and polymer coupled with strong performance from Tanfac. Margins have remained consistent this quarter, reflecting our focus on operational efficiency and a favourable product mix. While H1 FY25 was subdued due to weak macro conditions, I am pleased to share that H2 has shown clear signs of recovery — particularly in Q4 FY25 where we have seen meaningful improvement with sales increasing both year-on-year and sequentially. We remain confident in our ability to return to the historical growth rates achieved prior to the recent slowdown.” Result PDF
Conference Call with Anupam Rasayan India Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Anupam Rasayan India announced Q3FY25 results Total revenue for Q3FY25 was at Rs 3,866 million as compared to Rs 2,979 million in Q3FY24; up 30% YoY. EBITDA (incl. other income) was at Rs 1,208 million in Q3FY25 as compared to Rs 815 million in Q3FY24, up 48% and this would translate into 31% EBITDA margin in this quarter. Profit After Tax was at Rs 542 million in Q3FY25 as compared to Rs 260 million in Q3FY24; up 108% YoY. Anand Desai, Managing Director, Anupam Rasayan commented, “Our Pharma and Polymer segments, which have emerged as key growth drivers, continue to strengthen their contribution to our revenue. Both the segments coupled with strong performance of Tanfac led to significant growth this quarter, fueling a robust 31% QoQ revenue growth in Q3FY25 on a consolidated basis. For the full year, we expect them to play a substantial role in overall revenue, with this upward trend projected to continue into FY26. Additionally, the Agrochemical segment has shown signs of recovery, particularly in the European market." "With strong demand momentum and expected off-take from our customers, we anticipate regaining our growth trajectory in the next financial year, aiming for a 30-35% revenue increase in FY26. Result PDF